Investor Alert

New York Markets Close in:

Aug. 31, 2020, 1:52 a.m. EDT

Nestle to buy Aimmune Therapeutics in $2.6B deal

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Olivia Bugault

Nestle SA said Monday that it has entered into a definitive agreement for the acquisition of U.S.-based biopharmaceutical company Aimmune Therapeutics Inc. by its subsidiary Nestle Health Science, or NHSc.

Nestle will launch a cash tender offer for the acquisition of all Aimmune's outstanding shares not already owned by Nestle Health Science for a price of $34.50 per share, the Swiss food and beverage giant said. Including the roughly 25.6% equity stake that NHSc already owns in Aimmune, it represents a total enterprise value of $2.6 billion, Nestle said.

"The $34.50 per share acquisition price represents a 174% premium to Aimmune's closing share price on Aug. 28, 2020 of $12.60," it said.

The deal--which is expected to close in the fourth quarter of this year and financed by cash on hand--will be accretive to Nestle's organic growth in 2021 and add to cash earnings by 2022/2023, Nestle said.

"Aimmune's Palforzia is the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reaction to peanuts, including anaphylaxis, in children aged 4 through 17," Nestle said, adding that "the acquisition is an extension of NHSc's food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies."

Write to Olivia Bugault at olivia.bugault@wsj.com

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.